

Date: May 30, 2016

Hiran
ORGOCHEM LTD.

To,
The Manager,
Department of Corporate Services (DCS-Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001
Scrip Code: 506170

Dear Sir,

Ref.: Company Code: BSE - 506170

Sub: Submission of Annual Audited Financial Results along with the Audit Report for the quarter and financial year ended 31.03.2016 under Regulation 30 & 33 of SEBI (LODR) Regulations, 2015.

In terms of Regulation 30 read with Part B of Schedule III of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby enclose the following:

1. Standalone and Consolidated Annual Audited Financial Results of the Company for the quarter and year ended 31.03.2016 along with Auditor's Report.
2. Statement of Assets and Liabilities for the period ended 31.03.2016.

Please take the same on your record.

Thanking you,
Yours faithfully,
For Hiran Orgochem Limited,



Kantilal Mangalchand Hiran
Chairman & Managing Director
(DIN - 00186885)

Encl: As above

HIRAN ORGOCHEM LIMITED
Registered Off: Unit 908, 9th Floor, IJMIMA - Immitation Jewellery Market CSL, Raheja
Metroplex, Link Road, Malad (West) Mumbai-400064
CIN: L51900MH1983PLC029596
E-mail: anu@hiranorgochem.com Phone: 022-40144126/7
Website: www.hiranorgochem.com



Auditor's Report on Quarterly and Annual Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Hiran Orgochem Limited
Unit 908, 9th floor, IJMIMA-
Imitation Jewellery Mkt CSL,
Raheja Metroplex, Link Road, Malad (West)
Mumbai-400064

1. We have audited the accompanying standalone financial results of Hiran Orgochem Limited ("the Company") for the quarter ended March 31, 2016 and the year to date results for the period from April 1, 2015 to March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. These quarterly and annual standalone financial results have been prepared on the basis of standalone financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these standalone financial results based on our audit of such standalone financial statements, which have been prepared in accordance with Accounting Standard notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s).

An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.


3. In our opinion and to the best of our information and according to the explanations given to us these quarterly and annual financial results:
 - i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - ii. give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2016 as well as the year to date results for the period from April 1, 2015 to March 31, 2016.
4. Attention is drawn to the fact that the figures for the quarter ended March 31, 2016 as reported in these results are the balancing figures between audited figures in respect of the year ended March 31, 2016 and published year to date figures upto the end of third quarter of the relevant financial years. Also the figures upto the end of third quarter had only been reviewed and not subjected to audit.
5. Also, attention is drawn towards the following points -
 - a. Company's accounts with State Bank of India, State Bank of Patiala and SICOM Ltd have been classified as NPA by respective institutions and the Company has not provided interest on the same. Further in previous year, the loan of State Bank of India has been takeover by Edelweiss Asset Management Company.
 - b. During the previous year, all the fixed assets of the company were sold by Edelweiss Asset Management Company for 10.65 crores in an attempt to recover dues of State Bank of India. However management is of the view that company is a going concern.
 - c. Foreign Exchange gain/loss for the outstanding debtors and creditors is not recognised as per with AS -11 issued by ICAI.
 - d. In view of substantial loss, provision for deferred tax has not been considered in conformity with AS -22 issued by ICAI.
 - e. Company during the year has accumulated losses more than its share capital. However management is of the view that company is a going concern.
 - f. Company is in violation of Section 186 of Companies Act, 2013 with regards to limits specified relating to Loans & advances given by a company.
 - g. Company has provided interest free loan to a associate company, i.e. Actgen Pharma Private Limited, covered under section 189 of Companies Act, 2013. During the quarter Bank has taken possession of factory of Actgen Pharma Private Limited, an associate company, for which company has provided a corporate gurantee of 27 Crores. However as informed by the management to us the gurantee has not been invoked till date.



- h. Company is in process of compiling the details of pending assessments under various acts. Hence the impact of the same is not disclosed as contingent liability with respect to possible violations of any law applicable to the company.
- i. Company has also not rendered statutory dues with regards to Service Tax & Professional tax payable during the year.
- j. Company Secretary in Whole-Time Employment has resigned in February, 2016 and hence there was no Company Secretary as on 31st March, 2016 as required u/s 203 of Companies Act, 2013. However we are informed that Company is in process of appointing a new Company secretary in whole-time employment.

For & on Behalf of

MVK Associates
Chartered Accountants
Firm Registration Number: 120222W



CA Vishnu Garg
Partner
Membership. No. : 045560



Place : Mumbai
Date : May 30, 2016



Auditor's Report On Quarterly and Annual Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Hiran Orgochem Limited
Unit 908,9th floor, IJMIMA-
Immitation Jewellery Mkt CSL,
Raheja Metroplex, Link Road,Malad(West)
Mumbai-400064

1. We have the audited the accompanying consolidated financial results of Hiran Orgochem Limited ("the Company") and its associates for the quarter ended March 31, 2016 and the year to date results for the period from April 1, 2015 to March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. These quarterly and annual consolidated financial results have been prepared on the basis of consolidated financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated financial statements, which have been prepared in accordance with Accounting Standard notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s).

An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

3. We did not audit the financial statements of associates included in the consolidated financial results for the year ended on March 31, 2016 and for the

quarter ended on March 31, 2016; These financial statements are audited by another chartered accountant, figures and report of the same has been relied upon.

4. In our opinion and to the best of our information and according to the explanations given to us these quarterly and annual consolidated financial results:
 - i. includes the impact of financial results and year to date figures of the following associate entities:
 - Actgen Pharma Private Limited.
 - ii. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - iii. give a true and fair view of the consolidated net profit and other financial information for the quarter as well as for the year ended March 31, 2016.
5. Attention is drawn to the fact that the figures for the quarter ended March 31, 2016 as reported in these results are the balancing figures between audited figures in respect of the year ended March 31, 2016 and published year to date figures upto the end of third quarter of the relevant financial years. Also the figures upto the end of third quarter had only been reviewed and not subjected to audit.
3. Also, attention is drawn towards the following points -
 - a. Company's accounts with State Bank of India, State Bank of Patiala and SICOM Ltd have been classified as NPA by respective institutions and the Company has not provided interest on the same. Further in previous year, the loan of State Bank of India has been takenover by Edelweiss Asset Management Company.
 - b. During the previous year, all the fixed assets of the company were sold by Edelweiss Asset Management Company for 10.65 crores in an attempt to recover dues of State Bank of India. However management is of the view that company is a going concern.
 - c. Foreign Exchange gain/loss for the outstanding debtors and creditors is not recognised as per with AS -11 issued by ICAI.
 - d. In view of substantial loss, provision for deferred tax has not been considered in conformity with AS -22 issued by ICAI.
 - e. Company during the year has accumulated losses more than its share capital. However management is of the view that company is a going concern.
 - f. Company is in violation of Section 186 of Companies Act, 2013 with regards to limits specified relating to Loans & advances given by a company.
 - g. Company has provided interest free loan to a associate company, i.e. Actgen Pharma Private Limited, covered under section 189 of Companies Act, 2013. During the quarter Bank has taken possession of factory of Actgen Pharma




Private Limited, an associate company, for which company has provided a corporate gurantee of 27 Crores. However as informed by the management to us the gurantee has not been invoked till date.

- h. Company is in process of compiling the details of pending assesments under various acts. Hence the impact of the same is not disclosed as contingent liability with respect to possible violations of any law applicable to the company.
- i. Company has also not rendered statutory dues with regards to Service Tax & Professional tax payable during the year.
- j. Company Secretary in Whole-Time Employment has resigned in February, 2016 and hence there was no Company Secretary as on 31st March, 2016 as required u/s 203 of Companies Act, 2013. However we are informed that Company is in process of appointing a new Company secretary in whole-time employment.

For & on Behalf of

MVK Associates
Chartered Accountants
Firm Registration Number: 120222W



CA. Vishnu Garg
Partner
Membership. No. : 045560



Place : Mumbai
Date : May 30, 2016

HIRAN ORGOCHEM LIMITED

Registered Off: Unit 908,9th Floor, IJMIMA - Imitation Jewellery Market CSL, Raheja Metroplex, Link Road, Malad (West) Mumbai-400064,
CIN: L51900MH1983PLC029596

Phone: 022-40144126/7 **E-mail:** anu@hiranorgochem.com **Website:** www.hiranorgochem.com

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED AND YEAR ENDED AS ON 31ST MARCH, 2016								
(Amount in Rs. Lakh except Per Share Data)								
S. No.	Particulars	Standalone					Consolidated	
		QUARTER ENDED 31.03.2016 (Audited)	QUARTER ENDED 31.12.2015 (Unaudited)	QUARTER ENDED 31.03.2015 (Audited)	YEAR Ended 31.03.16 (Audited)	YEAR Ended 31.03.15 (Audited)	YEAR Ended 31.03.16 (Audited)	YEAR Ended 31.03.15 (Audited)
1	(a) Net Sales /Income from Operations	-	-	4.62	-	42.22	-	42.22
	(b) Other Operating Income	-	-	-	-	-	-	-
	Total Income from operation (a+b)	-	-	4.62	-	42.22	-	42.22
2	Expenditure							
	a) (Increase)/Decrease in stock in trade	-	-	-	-	-	-	-
	b) Purchase of Shares traded in	-	-	6.51	-	42.18	-	42.18
	c) Employees Benefit Expenses	3.27	3.87	3.36	15.66	13.29	15.66	13.29
	d) Depreciation	1.30	1.32	5.24	5.25	5.24	5.25	5.24
	e) Other Expenditure	8.64	(37.79)	3,018.56	(26.44)	3,049.90	(26.44)	3,049.90
	Total Expenditure (a+b+c+d+e)	13.20	(32.60)	3,033.67	(5.54)	3,110.62	(5.54)	3,110.62
3	Profit from Operations before Other Income, Interest & Exceptional Items & Tax (1-2)	(13.20)	32.60	(3,029.05)	5.54	(3,068.40)	5.54	(3,068.40)
4	Other Income	92.86	-	68.54	92.86	81.14	92.86	81.14
5	Profit before Interest & Exceptional items & Tax (3+4)	79.65	32.60	(2,960.51)	98.39	(2,987.26)	98.39	(2,987.26)
6	Finance Cost	6.30	0.01	(7.02)	6.38	(6.62)	6.38	(6.62)
7	Profit after interest but before Exceptional items (5-6)	73.36	32.59	(2,953.49)	92.02	(2,980.64)	92.02	(2,980.64)
8	Exceptional items	-	-	-	-	-	-	-
9	Profit (Loss) from Ordinary Activities before Tax (7+8)	73.36	32.59	(2,953.49)	92.02	(2,980.64)	92.02	(2,980.64)
10	Tax Expenses	-	-	-	-	-	-	-
11	Net Profit (Loss) from Ordinary Activities after Tax (9-10)	73.36	32.59	(2,953.49)	92.02	(2,980.64)	92.02	(2,980.64)
	Add/(Less) Tax Adjustments for earlier year	-	-	-	-	-	-	-
12	Extraordinary items (net of tax expenses)	-	-	-	-	-	-	-
13	Net Profit (Loss) for the period (11-12)	73.36	32.59	(2,953.49)	92.02	(2,980.64)	92.02	(2,980.64)
14	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	9,865.69	9,865.69	9,865.69	9,865.69	9,865.69	9,865.69	9,865.69
15	Reserves Excluding Revaluation Reserves	-	-	-	(16,101.51)	(13,325.87)	(16,101.51)	(13,325.87)
16	Earnings Per Share (EPS)							
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not annualized)	0.07	0.03	(2.99)	0.09	(3.02)	0.09	(3.02)
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not annualized)	0.07	0.03	(2.99)	0.09	(3.02)	0.09	(3.02)




**SEGMENT-WISE REVENUE AND RESULTS FOR THE QUARTER ENDED AND YEAR ENDED
AS ON MARCH 31, 2016**

PARTICULARS	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
	31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Segment Revenue(Net)					
Pharmaceuticals & Trading Chemicals	-	-	4.62	-	42.22
Construction	-	-	-	-	-
Gross revenues	-	-	4.62	-	42.22
Segment Results					
Profit before tax and Interest					
Pharmaceuticals & Trading Chemicals	(13.20)	32.60	(3,029.05)	5.54	(3,068.40)
Construction	-	-	-	-	-
Total Segment Results	(13.20)	32.60	(3,029.05)	5.54	(3,068.40)
Less : Finance cost	6.30	0.01	(7.02)	6.38	(6.62)
Add : Net unallocable Income	92.86	-	68.54	92.86	81.14
Total Profit before Tax	73.36	32.59	(2,953.49)	92.02	(2,980.64)
Segment Capital Employed					
(Segment Assets Less Segment Liabilities)					
Pharmaceuticals & Trading Chemicals	(1,475.42)	(757.68)	(1,523.61)	(1,475.42)	(1,523.61)
Construction	331.22	331.21	298.22	331.22	298.22
Unallocated Assets/(Liabilities)	(4,999.60)	(5,790.69)	(5,010.43)	(4,999.60)	(5,010.43)
Total Capital Employed	(6,143.80)	(6,217.16)	(6,235.82)	(6,143.80)	(6,235.82)

Notes :

- 1) Company's accounts with State Bank of India, State Bank of Patiala and SICOM Ltd have been classified as NPA by respective institution, hence the Company has not provided interest.
- 2) During the last year, all the fixed assets of the company are sold by Edelweiss Asset Management Company for 10.65 crores in an attempt to recover dues of State Bank of India. However, principle of going concern is not affected as per management.
- 3) Company is yet to transfer unclaimed dividends outstanding for a period of more than 7 years aggregating to Rs. 4.22 Lacs to Investors Protection Fund.
- 4) In view of substantial loss, provision for deferred tax has not been considered in conformity with AS -22 issued by ICAI.
- 5) Company during the year has accumulated losses more than its share capital. However, principle of going concern is not affected as per management.
- 6) Company's financial assets constitute more than 50 per cent of the total assets and income from financial assets constitute more than 50 per cent of the gross income. However Company is not registered under section 45-IA of the Reserve bank of India as its net owned funds are not adequate for registration as NBFC.
- 7) The figures for the quarter ended March 31, 2016 as reported in these results are the balancing figures between audited figures in respect of the year ended March 31, 2016 and published year to date figures upto the end of third quarter of the relevant financial years.
- 8) The above unaudited financial results for the quarter ended 31st March, 2016 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 30th May, 2016.

By order of the Board
For Hiran Orgochem Limited


Kantilal Hiran
Chairman & Managing Director
DIN:- 00126885

Place : Mumbai
Dated : 30th May, 2016

HIRAN ORGOCHEM LIMITED

Registered Off: Unit 908, 9th Floor, IJMIMA - Immitation Jewellery Market CSL, Raheja Metroplex, Link Road, Malad (West) Mumbai-400064, **Phone:** 022-40144126/7
CIN: L51900MH1983PLC029596 **E-mail:** anu@hiranorgochem.com **Website:** www.hiranorgochem.com

HIRAN ORGOCHEM LIMITED

(Amount in INR Lakh except Per Share Data)

Statement of Assets and Liabilities	Standalone		Consolidated	
	As At 31.03.16	As At 31.03.15	As At 31.03.16	As At 31.03.15
A. EQUITY AND LIABILITY				
1. Shareholders' Funds				
a. Share Capital	9,865.69	9,865.69	9,865.69	9,865.69
b. Reserves & Surplus	(16,009.49)	(16,101.51)	(16,009.49)	(16,101.51)
Sub Total - Shareholders' Funds	(6,143.80)	(6,235.82)	(6,143.80)	(6,235.82)
2. Share Application Money Pending Allotment	-	-	-	-
3. Non Current liabilities				
a. Long Term Borrowing	71.76	68.52	71.76	68.52
Sub Total - Non Current Liabilities	71.76	68.52	71.76	68.52
5. Current Liabilities				
a. Short Term Borrowing	6,452.54	6,477.00	6,452.54	6,477.00
b. Trade Payables	2,030.32	2,025.14	2,030.32	2,025.14
c. Other Current Liabilities	164.55	164.96	164.55	164.96
d. Short Term Provisions	50.78	49.43	50.78	49.43
Sub Total - Current Liabilities	8,698.19	8,716.53	8,698.19	8,716.53
TOTAL - EQUITY AND LIABILITIES	2,626.15	2,549.24	2,626.15	2,549.24
B. ASSETS				
1. Non Current Assets				
a. Fixed Assets				
i. Tangible Assets	14.61	19.85	14.61	19.85
ii. Capital WIP	-	-	-	-
b. Non Current Investments	-	-	-	-
c. Long Term Loans & Advances	-	-	-	-
Sub Total - Non Current Assets	14.61	19.85	14.61	19.85
2. Current Assets				
a. Current Investments	-	-	-	-
b. Inventories	107.22	107.22	107.22	107.22
c. Trade Receivables	24.28	36.56	24.28	36.56
d. Cash & Cash Equivalents	20.38	18.47	20.38	18.47
e. Short Term Loans & Advances	1,691.52	1,606.97	1,691.52	1,606.97
f. Other Current Assets	768.15	760.16	768.15	760.16
Sub Total - Current Assets	2,611.54	2,529.39	2,611.54	2,529.39
TOTAL - ASSETS	2,626.15	2,549.24	2,626.15	2,549.24

By order of the Board
For Hiran Orgochem Limited

Kantilal Hiran
Chairman & Managing Director
DIN:- 00186885



Place : Mumbai
Dated : 30th May, 2016

ANNEXURE I

**Statement on Impact of Audit Qualifications (for audit report with modified opinion)
submitted along-with Consolidated Annual Audited Financial Results**

Statement on Impact of Audit Qualifications for the financial year ended March 31, 2016. [See Regulation 33 / 52 of the SEBI (LODR) (Amendment) Regulations, 2016]				
I	Sl. No.	Particulars	Audited Figures (as reported before adjusting for qualifications) [Rs. In Lakhs]	Adjusted Figures (audited figures after adjusting for qualifications) [Rs. In Lakhs]
	1.	Turnover / Total income: Other Income	92.86	Management is unable to quantify the effect of * Qualifications. Hence, audited figures after adjusting for qualifications is not given.
	2.	Total Expenditure	0.84	
	3.	Net Profit/(Loss)	92.02	
	4.	Earnings Per Share	0.09	
	5.	Total Assets	2626.15	
	6.	Total Liabilities	2626.15	
	7.	Net Worth	(6143.80)	
	8.	Any other financial item(s) (as felt appropriate by the management)	--	
II	<u>Audit Qualification (each audit qualification separately):</u>			
	a. Details of Audit Qualification:			
	i. Foreign Exchange gain/loss for the outstanding debtors and creditors is not recognised as per with AS-11 issued by ICAI.			
	ii. Company is in violation of Section 186 of Companies Act, 2013 with regards to limits specified relating to loans & advances given by a company.			

Registered Off: Unit 908,9th Floor, IJMIMA - Immitation Jewellery Market CSL, Raheja Metroplex, Link Road, Malad (West) Mumbai-400064, **Phone:** 022-40144126/7

CIN: L51900MH1983PLC029596 **E-mail:** anu@hiranorgochem.com **Website:** www.hiranorgochem.com



- iii. Company has provided interest free loan to a associate company, i.e. Actgen Pharma Private Limited, covered under section 189 of Companies Act, 2013. During the quarter Bank has taken possession of factory of Actgen Pharma Private Limited, an associate company, for which company has provided a corporate guarantee of Rs. 27 Crores. However as informed by the management to us the guarantee has not been invoked till date.
- iv. Company is in process of compiling the details of pending assesments under various acts. Hence the impact of the same is not disclosed as contingent liability with respect to possible violations of any law applicable to the Company.
- v. Company has also not rendered statutory dues with regards to Service Tax & Professional tax payable during the year.

As a precaution, management hereby states the observations made by the Auditors in their Report for the best interest and for information purpose of Investors: (Points are self explanatory)

- vi. Company's accounts with State Bank of India, State Bank of Patiala and SICOM Ltd. have been classified as NPA by respective institutions and the Company has not provided interest on the same. Further in previous year, the loan of State Bank of India has been taken over by Edelweiss Asset Management Company.
- vii. During the previous year, all the fixed assets of the company were sold by Edelweiss Asset Management Company for 10.65 crores in an attempt to recover dues of State Bank of India. However management is of the view that Company is a going concern.
- viii. In view of substantial loss, provision for deferred tax has not been considered in conformity with AS-22 issued by ICAI.
- ix. Company during the year has accumulated losses more than its share capital. However management is of the view that Company is a going concern.
- x. Company Secretary in Whole-Time Employment has resigned in February, 2016 and hence there was no Company Secretary as on 31st March, 2016 as required u/s 203 of Companies Act, 2013. However we are informed that Company is in process of appointing a new Company secretary in whole-time employment.

b. Type of Audit Qualification : Qualified Opinion / Disclaimer of Opinion / Adverse Opinion

c. Frequency of qualification:



Whether appeared first time: Point No. II(a)(iii), II(a)(viii).

Repetitive: Point No. II(a)(i)-(ii),(iv)-(vii),(ix)-(x).



	d. For Audit Qualification(s) where the impact is quantified by the auditor, Management's Views: N.A.
	e. For Audit Qualification(s) where the impact is not quantified by the auditor:
	(i). Management's estimation on the impact of audit qualification: N.A.
	<p>(ii). If management is unable to estimate the impact, reasons for the same:</p> <p><u>Reply for Point II(a)(i):</u> Management is in the process of compiling details for quantifying the amount of foreign exchange gain/loss for the outstanding debtors and creditors.</p> <p><u>Reply for Point II(a)(ii):</u> The Company had obtained approval of shareholders via postal ballot for limit maximum upto Rs. 100 Crores as per the provisions of section 186 of the Companies Act, 2013.</p> <p><u>Reply for Point II(a)(iii):</u> The Board decided not to charge interest for the temporary loan given to associate company 'Actgen Pharma Pvt. Ltd.' in view of the business relationship and will charge the same in future as soon as the liquidity position of Actgen Pharma Pvt. Ltd. improves.</p> <p><u>Reply for Point II(a)(iv):</u> The assessments and demands are on stay and currently there is no movement in case as confirmed by company consultants.</p> <p><u>Reply for Point II(a)(v):</u> The management has to inform that the same has been noted and undisputed payments will be made.</p>
	<p>(iii). Auditors' Comments on (ii) above:</p> <p><u>Reply for Point II(a)(i):</u> The same is being noted.</p> <p><u>Reply for Point II(a)(ii):</u> Approval from Financial Institutions to be obtained.</p> <p><u>Reply for Point II(a)(iii):</u> The same is being noted.</p> <p><u>Reply for Point II(a)(iv):</u> The complete details of the same are required.</p> <p><u>Reply for Point II(a)(v):</u> The same is being noted.</p>



III	Signatories:	
	• Chairman & Managing Director	
	• Director	११/२२/११/११
	• Audit Committee Chairman	Ban... ..
	• Statutory Auditor	
	Place: Mumbai	
	Date: May 30, 2016	



ANNEXURE I

**Statement on Impact of Audit Qualifications (for audit report with modified opinion)
submitted along-with Standalone Annual Audited Financial Results**

Statement on Impact of Audit Qualifications for the financial year ended March 31, 2016. [See Regulation 33/52 of the SEBI (LODR) (Amendment) Regulations, 2016]				
I	Sl. No.	Particulars	Audited Figures (as reported before adjusting for qualifications) [Rs. In Lakhs]	Adjusted Figures (audited figures after adjusting for qualifications) [Rs. In Lakhs]
	1.	Turnover / Total income: Other Income	92.86	Management is unable to quantify the effect of Qualifications. Hence, audited figures after adjusting for qualifications is not given.
	2.	Total Expenditure	0.84	
	3.	Net Profit/(Loss)	92.02	
	4.	Earnings Per Share	0.09	
	5.	Total Assets	2626.15	
	6.	Total Liabilities	2626.15	
	7.	Net Worth	(6143.80)	
	8.	Any other financial item(s) (as felt appropriate by the management)	--	
II	<u>Audit Qualification (each audit qualification separately):</u>			
	a. Details of Audit Qualification:			
	i. Foreign Exchange gain/loss for the outstanding debtors and creditors is not recognised as per with AS-11 issued by ICAI.			
	ii. Company is in violation of Section 186 of Companies Act, 2013 with regards to limits specified relating to loans & advances given by a company.			



- iii. Company has provided interest free loan to a associate company, i.e. Actgen Pharma Private Limited, covered under section 189 of Companies Act, 2013. During the quarter Bank has taken possession of factory of Actgen Pharma Private Limited, an associate company, for which company has provided a corporate guarantee of Rs. 27 Crores. However as informed by the management to us the guarantee has not been invoked till date.
- iv. Company is in process of compiling the details of pending assesments under various acts. Hence the impact of the same is not disclosed as contingent liability with respect to possible violations of any law applicable to the Company.
- v. Company has also not rendered statutory dues with regards to Service Tax & Professional tax payable during the year.

As a precaution, management hereby states the observations made by the Auditors in their Report for the best interest and for information purpose of Investors: (Points are self explanatory)

- vi. Company's accounts with State Bank of India, State Bank of Patiala and SICOM Ltd. have been classified as NPA by respective institutions and the Company has not provided interest on the same. Further in previous year, the loan of State Bank of India has been taken over by Edelweiss Asset Management Company.
- vii. During the previous year, all the fixed assets of the company were sold by Edelweiss Asset Management Company for 10.65 crores in an attempt to recover dues of State Bank of India. However management is of the view that Company is a going concern.
- viii. In view of substatial loss, provision for deferred tax has not been considered in conformity with AS-22 issued by ICAI.
- ix. Company during the year has accumulated losses more than its share capital. However management is of the view that Company is a going concern.
- x. Company Secretary in Whole-Time Employment has resigned in February, 2016 and hence there was no Company Secretary as on 31st March, 2016 as required u/s 203 of Companies Act, 2013. However we are informed that Company is in process of appointing a new Company secretary in whole-time employment.

b. Type of Audit Qualification : Qualified Opinion / Disclaimer of Opinion / Adverse Opinion

c. Frequency of qualification:





Whether appeared first time: Point No. II(a)(iii), II(a)(viii).

Repetitive: Point No. II(a)(i)-(ii),(iv)-(vii),(ix)-(x).



	d. For Audit Qualification(s) where the impact is quantified by the auditor, Management's Views: N.A.
	e. For Audit Qualification(s) where the impact is not quantified by the auditor:
	(i). Management's estimation on the impact of audit qualification: N.A.
	<p>(ii). If management is unable to estimate the impact, reasons for the same:</p> <p>Reply for Point II(a)(i): Management is in the process of compiling details for quantifying the amount of foreign exchange gain/loss for the outstanding debtors and creditors.</p> <p>Reply for Point II(a)(ii): The Company had obtained approval of shareholders via postal ballot for limit maximum upto Rs. 100 Crores as per the provisions of section 186 of the Companies Act, 2013.</p> <p>Reply for Point II(a)(iii): The Board decided not to charge interest for the temporary loan given to associate company 'Actgen Pharma Pvt. Ltd.' in view of the business relationship and will charge the same in future as soon as the liquidity position of Actgen Pharma Pvt. Ltd. improves.</p> <p>Reply for Point II(a)(iv): The assessments and demands are on stay and currently there is no movement in case as confirmed by company consultants.</p> <p>Reply for Point II(a)(v): The management has to inform that the same has been noted and undisputed payments will be made.</p>
	<p>(iii). Auditors' Comments on (ii) above:</p> <p>Reply for Point II(a)(i): The same is being noted.</p> <p>Reply for Point II(a)(ii): Approval from Financial Institutions to be obtained.</p> <p>Reply for Point II(a)(iii): The same is being noted.</p> <p>Reply for Point II(a)(iv): The complete details of the same are required.</p> <p>Reply for Point II(a)(v): The same is being noted.</p>



III	Signatories:	
	• Chairman & Managing Director	
	• Director	
	• Audit Committee Chairman	
	• Statutory Auditor	
	Place: Mumbai	
	Date: May 30, 2016	

